ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs
May 08 2023 - 8:30AM
ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech,
genomics and diagnostics company, today announced that Dr. Matthew
Halpert has been hired as a full-time consultant to drive the
Company’s key therapeutic and diagnostic programs forward which
will comprise the backbone of ProPhase’s efforts in both advanced
cancer therapeutics and targeted cancer diagnostics.
Dr. Halpert will assist with several ongoing
programs at ProPhase BioPharma (PBIO) including Linebacker-1
initiatives as a cancer mono-therapy as well as to be developed as
a potential co-therapy with multi-billion-dollar drugs like
Doxorubicin. LB-1 is currently going into xenograft (mouse) studies
in collaboration with the Dana Farber Cancer Institute and Harvard
University scientists with the goal of completing a Phase 1 human
clinical trial in 2024. Dr. Halpert will also assist with the
BE-Smart Esophageal Cancer Test that is expected to advance into
validation studies by Q4 2023 for research use only (RUO) testing
and broad commercialization with CPT codes in early 2024. Dr.
Halpert will work closely with our ProPhase team in finalizing
human clinical trials for Equivir, a broad-based anti-viral to be
marketed as a dietary supplement that is expected to be
commercialized by Q4 2023. Dr. Halpert will also assist the
ProPhase team on other new and exciting programs which will be
announced at a later date as they advance in pre-clinical
testing.
Dr. Matthew Halpert, Ph.D. earned his doctorate
at the University of Alabama-Birmingham (UAB), and then spent 10
years at Baylor College of Medicine in Houston as a cancer
immunologist. His research in the space of ‘immunity’ and ‘novel
cancer treatments’ lead to several peer-reviewed publications and
book chapters, hundreds of citations, a variety of patents,
positions on multiple charitable boards, and establishment as one
of the leading experts regarding cutting-edge mechanistic science
as it pertains to the treatment of cancer. While an academic
researcher, he launched both a Cancer focused charity and a Cancer
Research company which has taken some of the most advanced
immunotherapy unique to Dr. Halpert’s research into several FDA
clinical trials, all of which are currently showing signs of
significance. As an efficient, motivated, science-business hybrid
with demonstrated experience in taking forward-thinking academic
discoveries into the FDA pathways in commercially viable spaces,
Dr. Halpert left academia to further assist in bridging the gap
between “solid, foundational science” and “clinical applicability.”
In that vein, Dr. Halpert has joined the Company to expedite
multiple innovative technologies towards approved, practical
inclusion in the clinic where people in need will truly see their
lives transformed.
“Having started several oncology focused
companies, Dr. Halpert is perfectly qualified to help ProPhase
develop Linebacker-1 as both a mono-therapy and co-therapy in
several difficult to treat cancers,” commented Ted Karkus, CEO of
ProPhase Labs.” “Dr. Halpert will be a key participant in trial
design, regulatory preparation and the potential commercialization
of numerous therapeutic products at the Company. Dr Halpert has
both the expertise and experience to assist and guide PBIO assets
through all regulatory steps toward commercialization.”
“Dr. Halpert has a unique perspective and strong
track record as an objective and well-regarded scientist. He also
understands how to execute along the pathway toward clinical
inclusion and FDA approvability with an unmatched passion,” praised
Ted Karkus, CEO of ProPhase Labs. “He will be working very closely
with our team to expedite a cutting-edge Esophageal Cancer Test
which has multi-billion-dollar potential and could be
commercialized with CPT insurance codes in potentially less than 12
months, the multi-faceted Linebacker cancer treatment, and Equivir
as a broad based anti-viral option (OTC/dietary supplement and
Rx).”
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”)
is a next-generation biotech, genomics and diagnostics company. Our
goal is to create a healthier world with bold action and the power
of insight. We’re revolutionizing healthcare with industry-leading
Whole Genome Sequencing solutions, while developing potential game
changer diagnostics and therapeutics in the fight against cancer.
This includes a potentially life-saving cancer test focused on
early detection of esophageal cancer and potential breakthrough
cancer therapeutics with novel mechanisms of action. Our
world-class CLIA labs and cutting-edge diagnostic technology
provide wellness solutions for healthcare providers and consumers.
We develop, manufacture, and commercialize health and wellness
solutions to enable people to live their best lives. We are
committed to executional excellence, smart diversification, and a
synergistic, omni-channel approach. ProPhase Labs’ valuable
subsidiaries, their synergies, and significant growth underscore
our multi-billion-dollar potential.
Forward Looking Statements
Except for the historical information contained
herein, this document contains forward looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding our strategy, plans,
objectives and initiatives and projected timelines for its
preclinical and clinical programs and commercialization. Management
believes that these forward-looking statements are reasonable as
and when made. However, such forward-looking statements involve
known and unknown risks, uncertainties, and other factors that may
cause actual results to differ materially from those projected in
the forward-looking statements. These risks and uncertainties
include but are not limited to our ability to obtain and maintain
necessary regulatory approvals, general economic conditions,
consumer demand for our products and services, challenges relating
to entering and growing new business lines, the competitive
environment, and the risk factors listed from time to time in our
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any
other SEC filings. The Company undertakes no obligation to update
forward-looking statements except as required by applicable
securities laws. Readers are cautioned that forward-looking
statements are not guarantees of future performance and are
cautioned not to place undue reliance on any forward-looking
statements.
For more information, visit
www.ProPhaseLabs.com.
Media Relations and Institutional
Investor Contact:
ProPhase Labs, Inc.
267-880-1111investorrelations@prophaselabs.com
Retail Investor Relations
Contact:
Renmark Financial CommunicationsJohn
Boidman514-939-3989Jboidman@renmarkfinancial.com
Source: ProPhase Labs, Inc.
###
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2024 to May 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From May 2023 to May 2024